#Israel #Elfabrio #PRX-115 #Protalix #Carmeil

Protalix BioTherapeutics Reports Impressive Third Quarter Results

Protalix BioTherapeutics, a biopharmaceutical entity focused on innovative therapies for rare diseases, recently unveiled its financial results for the third quarter of 2026, highlighting noteworthy progress and a promising trajectory for the future. The company recorded total revenues surging to $75.6 million for the first nine months of 2026, representing a substantial increase from $43.6 million in the corresponding period of the previous year. This increase is primarily a result of enhanced sales to strategic partners, particularly Chiesi, with whom Protalix has a collaborative agreement for the development and commercialization of some of its therapeutic products.

In the third quarter alone, the company achieved a net income of $4 million, which marks a commendable leap from the $2.4 million for the same period in 2025. Looking ahead, Protalix has reiterated its revenue forecast for 2026, anticipating total revenues between $78 and $83 million, which underscores its commitment to maintaining financial robustness amidst evolving market dynamics.

The company’s cash position also reflects its solid operational status, with cash and liquid assets totaling $48.5 million as of September 30, 2026. This financial stability enables Protalix to continue its research initiatives, particularly the advancement of PRX-115, a recombinant PEGylated uricase currently in Phase 2 clinical trials aimed at treating uncontrolled gout, a condition marked by high unmet needs in patient care.

Advancements in Clinical Research

Protalix has made strides in its clinical programs, particularly with PRX-115. The ongoing RELEASE study (NCT07280156) is pivotal for demonstrating the efficacy of this novel therapy, which aims to enhance patient adherence through less frequent dosing and improved tolerability. PRX-115 is engineered to reduce infusion burden, a common hurdle in current uricase treatments, thereby hopeful in addressing the unmet need in gout patients. Early indications suggest potential for PRX-115 to become a leading treatment for those suffering from uncontrolled gout, with top-line results from this trial expected in late 2027.

Moreover, Protalix celebrated a significant milestone with Elfabrio’s recent marketing authorization in Brazil, expanding options for patients with Fabry disease, thereby reinforcing the company’s flexibility and commitment in navigating regulatory regions effectively.

Financial Overview and Key Highlights

During the third quarter, Protalix's revenue from sales amounted to $21.8 million, while for the first nine months, it reached $49.1 million, marking increases of $4.1 million and $6 million respectively from the same periods in 2025. This uplift can be attributed primarily to higher demand from Chiesi for Elfabrio and Elelyso®, culminating in key financial performance metrics that indicate a thriving operational environment.

Research and development expenses did elevate to $6.9 million for the third quarter, aimed at propelling advancements in ongoing studies, including those for PRX-115. The company's strategies include supporting its commercial partners and pushing its pipeline of therapies with a keen eye toward innovation and patient-centered care.

The financial dynamics outlined above fortify Protalix’s vision of building a sustained growth approach towards a more resilient and diversified portfolio, by not only capitalizing on current successes but also innovating within the field of biopharmaceuticals.

Conference Call and Future Prospects

Protalix is set to host a conference call today to elaborate on its financial outcomes, followed by a live webcast. The company aims to provide more comprehensive insights into its operational strategy and the anticipated timelines for its clinical study results. Attendees are encouraged to access the conference using the provided links, ensuring they are well-prepared ahead of time.

Overall, the third-quarter report from Protalix BioTherapeutics exudes confidence, showcasing an upswing in both revenue and clinical advancements, with a strategic focus on addressing critical health needs in rare diseases. As they continue towards their path of innovation, stakeholders remain optimistic about the firm’s future performance and contributions to the biopharmaceutical landscape.